I'm sorry, Ms. Devine, I have a second question. Perhaps you can start with this one.
Following up on what Mr. Martin said, respectfully I would say the big problem here is that we're setting up a model where you're just allowing....
Any time you get into patent legislation, the same as competition legislation or a lot of other legislation, it's so complicated and involves so many interests. It seems to me that Mr. Martin's question is completely valid in the sense that it says, let's step outside of that and let's put out an RFP, and let's in fact realize that the brand names are the ones actually creating these medicines in the first place, and then you give them an opportunity. He said you simplify the licence system.
That seems to me to be an entirely valid question, especially with the amount of foundation funds that are out there with the Gates Foundation and other foundations. It seems to me much simpler to actually say, here's what the Government of Canada is coming to the table with through CIDA, here's perhaps the Gates Foundation, and here's an opportunity for either the brand name or the generic to come forward and supply the medicine. The goal is to get the medicine from here to a person, as Mr. Fox said, so that person's life improves. It's not to get involved in a patent debate in Canada.
Ms. Devine, maybe you want to respond to that again.